In this webinar, Prof. Jörn Schattenberg discussed his paper in Nature Reviews Gastroenterology & Hepatology on effective and efficient models of care for patients with NAFLD. Standardized patient care pathways for NAFLD are not yet widely im...
Hosted by: Julius Clinical.Speakers:Pieter van Bokhoven | CSO| IAO Amsterdam Neuroscience AUMC Jort Vijverberg | Neurologist | Amsterdam Neuroscience AUMCTopics that are discussed during this webinar:All major trends in Alzh...
Topics that has been discussed:The Impact of NAFLD/NASH What is being done to tackle NAFLD/NASH globally and nationally What still needs to be done in the fight against NAFLD/NASH How can you/your country advance the battle against ...
Genome-wide association studies have uncovered robust and reproducible associations between several genetic variations and the natural history of NAFLD. During this webinar, Professor Eric Trépo reviewed these findings that have provided compelli...
We presented the webinar COVID-19 lessons from pandemic to endemic. During this webinar Prof. Jerome H. Kim, Director General of the International Vaccine Institute (IVI), discussed:- Pandemic preparedness – lessons learned - Clinical Devel...
Together with our partner TRICALS, we presented the webinar: Efficient Patient Identification in ALS Clinical Trials; Leveraging the Concept of Fast and Slow Progressors.During this webinar, Prof. Dr. L.H. van den Berg and R.P.A van Eijk talke...
During this webinar Prof. Sven Francque discussed the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (p...
This webinar focussed on the close multilevel links between insulin resistance/T2DM and NAFLD.Topics that are discussed:Epidemiological links between NAFLD, insulin resistance and T2DM Insulin resistance as root cause of NAFLD: mechan...
Together with our partner Brain Research Center, we presented the webinar: Innovative Endpoints in Alzheimer’s Disease Clinical trials.During this webinar, two experts in the field, Dr. Niels Prins and Dr. Jort Vijverberg discussed the ...
Given the high prevalence of NAFLD in the general population, identifying the persons at a high risk for development of cirrhosis is key. During this presentation, Professor Hannes Hagström focussed on methods and strategies to achieve this in di...
"*" indicates required fields
"*" indicates required fields
